A Novel Necroptosis-Related Signature Can Predict Prognosis and Chemotherapy Sensitivity in Multiple Myeloma.
Journal Information
Full Title: Technol Cancer Res Treat
Abbreviation: Technol Cancer Res Treat
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Evidence found in paper:
"this prospective study included 858 mm samples from the multiple myeloma research foundation (mmrf) commpass database and 559 mm samples from the gene expression omnibus (geo) database which included the gse2658 cohort with survival data."
Code Sharing
COI Disclosure
Evidence found in paper:
"The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article."
Funding Disclosure
Evidence found in paper:
"Funding: The study was funded by National Natural Science Foundation of China (82160405) and the Natural Science Foundation of Jiangxi Province (20232BAB216037)."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025